Amgen Inc. (AMGN)
$
364.65
-11.17 (-3.06%)
Key metrics
Financial statements
Free cash flow per share
15.0278
Market cap
196.4 Billion
Price to sales ratio
5.3447
Debt to equity
6.3068
Current ratio
1.1400
Income quality
1.2914
Average inventory
6.3 Billion
ROE
0.9665
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. The company reported an income before tax of $8,976,000,000.00 showcasing its pre-tax profitability. The EBITDA is $17,132,999,000.00 a key indicator of the company's operational profitability, while the operating income ratio is 0.41 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.83 reflecting the efficiency of the company's production and sales operations. The company's stock is identified with the symbol 'AMGN' in the market, representing a significant asset for investors. Amgen's product portfolio includes treatments such as Enbrel for plaque psoriasis and rheumatoid arthritis, Neulasta for patients with low white blood cell counts due to cancer, Prolia for osteoporosis in postmenopausal women, and Repatha to reduce cardiovascular risks, among others. It also engages in several collaboration agreements to develop innovative therapies, such as its partnership with Novartis Pharma AG and Kyowa Kirin Co., Ltd. Trading at a price of $285.41 the stock is positioned in the higher-end market, reflecting the company's strong market presence. Furthermore, the stock has a high average trading volume of 2,947,355.00 indicating strong liquidity and investor interest. With a large market capitalization of $196,357,096,650.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. Amgen Inc. operates within the Healthcare sector, driving innovation and growth through its cutting-edge research and product development. Its offerings, including Otezla, Aranesp, and KYPROLIS, illustrate its commitment to providing impactful therapies for various health conditions. By serving healthcare providers across multiple channels, including hospitals and pharmacies, Amgen focuses on delivering solutions that enhance patient outcomes. The company's collaborations with firms like Neumora Therapeutics and Plexium underscore its strategic approach to expanding its therapeutic portfolio, positioning it to remain a key player in a constantly evolving industry.
Is Amgen Inc. (AMGN) a good investment?
Investing in Amgen Inc. (AMGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Amgen Inc. (AMGN)'s stock forecast?
Analysts predict Amgen Inc. stock to fluctuate between $261.43 (low) and $385.12 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Amgen Inc.'s market capitalization?
As of 2026-02-10, Amgen Inc.'s market cap is $196,357,096,650, based on 538,481,000 outstanding shares.
How does Amgen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Amgen Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Amgen Inc. pay dividends?
Amgen Inc. pays dividends. The current dividend yield is 2.65%, with a payout of $2.52 per share.
How can I buy Amgen Inc. (AMGN) stock?
To buy Amgen Inc. (AMGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AMGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Amgen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Amgen Inc. stock ever split?
Amgen Inc.'s last stock split was 2:1 on 1999-11-22.
How did Amgen Inc. perform in the last earnings report?
Revenue: $36,751,000,000 | EPS: $14.33 | Growth: 88.06%.
Where can I find Amgen Inc.'s investor relations reports?
Visit https://www.amgen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Amgen Inc.?
You can explore historical data from here
What is the all-time high and low for Amgen Inc. stock?
All-time high: $385.12 (2026-02-06) | All-time low: $198.64 (2021-12-01).
What are the key trends affecting Amgen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
defenseworld.net
Ironwood Investment Counsel LLC raised its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 15.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,934 shares of the medical research company's stock after acquiring an additional 2,107 shares during the quarter.
zacks.com
Amgen ( AMGN ) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in.
zacks.com
Amgen delivers Q4 earnings and revenue beat, driven by strong drug volumes, as attention turns to its late-stage MariTide obesity studies.
forbes.com
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in the global market.
seekingalpha.com
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
zacks.com
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
wsj.com
The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue and lower net unrealized losses on equity investments.
defenseworld.net
Atle Fund Management AB decreased its holdings in Amgen Inc. (NASDAQ: AMGN) by 42.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,806 shares of the medical research company's stock after selling 10,088 shares during the period. Amgen makes up about 1.5% of
defenseworld.net
National Pension Service boosted its holdings in Amgen Inc. (NASDAQ: AMGN) by 3.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,184,060 shares of the medical research company's stock after purchasing an additional 37,747 shares during the quarter. National Pension Service
See all news
